All News
Filter News
Found 808,890 articles
-
Hemovent to introduce innovative and recently CE-marked MOBYBOX® at ELSO annual meeting
9/9/2019
Hemovent GmbH announced today that it will introduce its MOBYBOX™ ECMO / ECLS system at the upcoming annual meeting of ELSO (Extracorporeal Life Support Organization) in Austin, Tex., Sept. 12-15.
-
FDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications
9/9/2019
Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that the U.S. Food & Drug Administration (FDA) has granted Fast Track designations for both the intravenous (IV) and oral formulations of the company's lead antifungal candidate, fosmanogepix (APX001
-
AgeX Therapeutics Presents at the Rodman & Renshaw Global Investment Conference
9/9/2019
AgeX Therapeutics, Inc. announced that founder and CEO Michael D. West, Ph.D. is presenting at the 21st Annual Rodman & Renshaw Global Investment Conference at the New York Palace Hotel in New York City.
-
Paradigm's Michael Choo, MD Joins External Collaborative Panel of National Limb Loss and Preservation Registry
9/9/2019
The registry aims to help patients, healthcare providers, and clinicians better understand the treatment and surgical options for limb preservation and/or amputation.
-
Arena Pharmaceuticals Presented New Patient-Reported Outcomes Data for Olorinab at the European Society of Neurogastroenterology & Motility NeuroGASTRO 2019 Meeting
9/9/2019
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new patient-reported outcomes data for olorinab, an investigational, oral, peripherally acting, highly-selective, full agonist of the cannabinoid receptor 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal (GI) disorders, at the European Society of Neurogastroenterology & Motility (ESNM) 2019 NeuroGASTRO Meeting.
-
Cerevel Therapeutics Appoints Biotechnology Leader Tony Coles, M.D., as Chief Executive Officer
9/9/2019
Dr. Coles assumes his new role at an important time as the company prepares to launch six clinical trials by the end of 2020 to advance its robust and diverse neuroscience pipeline
-
Ground-Breaking Single-Cell Transcriptomic Study Using ICELL8® Technology Reveals Homogeneity in Mono- and Multi-Nucleated Adult Cardiomyocytes
9/9/2019
Their work, which appeared recently in Basic Research in Cardiology, elucidated transcriptomic signatures of these cardiomyocytes during induced cardiac hypertrophy.
-
Neurotrope Announces Top-line Results From Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease
9/9/2019
An average increase in SIB total score of 1.3 points and 2.1 points was observed for the Bryostatin-1 and placebo groups, respectively, at Week 13.
-
Tilray, Inc. and Privateer Holdings, Inc. Sign Definitive Agreement to Extend Lock-up and Provide for Orderly Distribution of 75 Million Tilray Shares Held by Privateer
9/9/2019
Tilray, Inc. (NASDAQ: TLRY), a global leader in cannabis research, cultivation, production, and distribution, today announced that it has signed a definitive merger agreement with its largest stockholder Privateer Holdings, Inc. (“Privateer”) for a transaction that will extend the lock-up on and provide for the issuance of up to 75 million Tilray shares to Privateer’s equity holders (and the cancellation of the 75 million shares currently owned by Privateer).
-
SkinTE Data to be Presented at the American Society of Plastic Surgeons 88th Annual Scientific Meeting
9/9/2019
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that an abstract with data from 15 patient cases where the Company's SkinTE™ product was used to treat a variety of wounds was accepted for a podium presentation at the American Society of Plastic Surgeons' scientific meeting, Plastic Surgery The Meeting,
-
Ideal Image MedSpa Raises Awareness for PCOS
9/9/2019
Leading Skin, Face & Body MedSpa announces support for national PCOS Awareness Month
-
Acceleron Receives FDA Orphan Drug Designation for Sotatercept in Pulmonary Arterial Hypertension
9/9/2019
Acceleron Pharma Inc announced that the United States Food and Drug Administration has granted Orphan Drug designation to sotatercept for the treatment of patients with pulmonary arterial hypertension.
-
Gyros Protein Technologies introduces Gyrolab p24 Kit to support the cell and gene therapy market
9/9/2019
Ready-to-use kit enables lentivirus titer determinations during the manufacture of lentivirus vectors
-
Cesca Therapeutics And ThermoGenesis Announce Major Global Distribution Agreement For The Company's X-Series® Products
9/9/2019
The Company will receive a $2 million upfront distribution fee, and future market support for granting the exclusive rights.
-
Personalis, Inc. Enters Into Research Agreement With Invectys to Provide Comprehensive Tumor Immunogenomics Profiling for Clinical Trial
9/9/2019
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that it has entered into a research agreement with Invectys, a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers
-
Proliant Biologicals Acquires Boval BioSolutions from Lifecycle Biotechnologies
9/9/2019
Proliant Biologicals, LLC (Proliant), an LGI company (Lauridsen Group Inc.), today announced that it has acquired Boval BioSolutions from Lifecycle Biotechnologies of Fort Worth, TX.
-
Viela Bio Announces Data Presentations at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
9/9/2019
Viela Bio announced that data from the N-MOmentum trial—the largest global, placebo-controlled study conducted in patients with neuromyelitis optica spectrum disorder—have been selected for an oral plenary session presentation as well as poster presentations at the upcoming 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
-
Netech Obtains FDA 510(k) Clearance for Delta 3300 - Defibrillator/Pacemaker Analyzer
9/9/2019
Delta 3300 Is A Compact and Light Weight Precision Instrument Ideal for Testing all Defibrillators and Pacemakers
-
Addus HomeCare Announces Closing of Public Offering and Exercise of Option to Purchase Additional Shares
9/9/2019
The net proceeds to the Company from the offering were approximately $172.9 million, after deducting underwriting discounts and estimated offering expenses.
-
Biodesix Highlights Clinical Data Demonstrating the Potential of EarlyCDT Lung Blood Test to Improve Early Detection of Lung Cancer
9/9/2019
Biodesix, Inc. today highlighted positive clinical data from Oncimmune’s EarlyCDT Lung® blood test, which harnesses the power of the immune system to detect evidence of the body’s natural response to cancer.